secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shattuck Labs, Inc. (STTK)
CIK:        0001680367
Form:       8-K
Filed at:   2024-10-01T23:59:59+00:00
Accession:  0001193125-24-229480
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 1.02, 2.05, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shattuck Labs discontinues SL-172154, cuts 40% workforce, pivots to DR3 antagonist SL-325
--------------------------------------------------------------------------------

- Discontinued SL-172154 after interim OS data showed only modest improvement vs azacitidine monotherapy in TP53m AML/HR-MDS.
- Plans to focus on SL-325, a first-in-class DR3 antagonist antibody for IBD; IND filing expected Q3 2025.
- Approximately 40% workforce reduction; expects restructuring charges of $1.5M-$1.75M in Q4 2024.
- Cash runway extended into 2027, with $105.3M cash, cash equivalents and investments as of June 30, 2024.
- Mutually terminated collaboration with Ono Pharmaceutical; no future reimbursements, milestones, or royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680367/000119312524229480/0001193125-24-229480-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680367/000119312524229480/d845252d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-229480

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer